CEPHALON INC - FORM 8-K - September 26, 2011

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported)  September 23, 2011

 

Cephalon, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Registrant’s telephone number, including area code  (610) 344-0200

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01                                             Other Events.

 

On September 23, 2011, Cephalon, Inc. (the “Company”) received a subpoena duces tecum from the U.S. Attorney’s Office for the Southern District of New York pursuant to its authority under the Health Insurance Portability and Accountability Act requesting records regarding TREANDA® (bendamustine hydrochloride). The Company is in the process of responding to the subpoena and intends to cooperate fully.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

		CEPHALON, INC.
Date: September 26, 2011		By:	/s/ Gerald J. Pappert
			Gerald J. Pappert
			Executive Vice President and General Counsel

 

3